eicosapentaenoic acid ethyl ester has been researched along with Myocardial Infarction in 14 studies
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Results from the Colchicine Cardiovascular Outcomes Trial (COLCOT) showed that low-dose colchicine reduces the risk of recurrent CVD events among patients with recent myocardial infarction." | 5.05 | Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions. ( Blumenthal, RS; Gulati, M; Mahtta, D; Mehta, A; Sperling, LS; Virani, SS, 2020) |
| "To assess the cost effectiveness of icosapent ethyl, fenofibrate, ezetimibe, evolocumab, and alirocumab in combination with statins compared to statin monotherapy for cardiovascular prevention from the perspective of UK's National Health Service." | 1.72 | Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. ( Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T, 2022) |
| " Taken together, chronic use of icosapent ethyl after infarction is associated with up-regulation of connexin43 phosphorylation through a GPR120-dependent antioxidant pathway and thus plays a beneficial effect on arrhythmogenic response to programmed electrical stimulation." | 1.56 | Effect of icosapent ethyl on susceptibility to ventricular arrhythmias in postinfarcted rat hearts: Role of GPR120-mediated connexin43 phosphorylation. ( Chen, SY; Chen, WT; Lee, CC; Lee, TM; Wu, DW, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 12 (85.71) | 2.80 |
| Authors | Studies |
|---|---|
| Gaba, P | 2 |
| Bhatt, DL | 6 |
| Giugliano, RP | 4 |
| Steg, PG | 6 |
| Miller, M | 5 |
| Brinton, EA | 5 |
| Jacobson, TA | 5 |
| Ketchum, SB | 4 |
| Juliano, RA | 4 |
| Jiao, L | 5 |
| Doyle, RT | 4 |
| Granowitz, C | 5 |
| Tardif, JC | 5 |
| Ballantyne, CM | 5 |
| Pinto, DS | 1 |
| Budoff, MJ | 3 |
| Gibson, CM | 4 |
| Peterson, BE | 1 |
| Pinto, D | 1 |
| Verma, S | 1 |
| Martens, FMAC | 1 |
| Boden, WE | 1 |
| Andersson, C | 1 |
| Michaeli, DT | 1 |
| Michaeli, JC | 1 |
| Boch, T | 1 |
| Michaeli, T | 1 |
| Budoff, M | 1 |
| Mason, RP | 1 |
| Olshansky, B | 1 |
| Chung, MK | 1 |
| Mehta, A | 1 |
| Mahtta, D | 1 |
| Gulati, M | 1 |
| Sperling, LS | 1 |
| Blumenthal, RS | 1 |
| Virani, SS | 1 |
| Chen, WT | 1 |
| Chen, SY | 1 |
| Wu, DW | 1 |
| Lee, CC | 1 |
| Lee, TM | 1 |
| Wong, ND | 1 |
| Fan, W | 1 |
| Philip, S | 1 |
| Toth, PP | 1 |
| Myran, L | 1 |
| Nguyen, TN | 1 |
| Picard, F | 1 |
| Ducrocq, G | 1 |
| Ohman, EM | 1 |
| Goto, S | 1 |
| Eagle, KA | 1 |
| Wilson, PWF | 1 |
| Smith, SC | 1 |
| Elbez, Y | 1 |
| Lan, NSR | 1 |
| Fegan, PG | 1 |
| Yeap, BB | 1 |
| Rankin, JM | 1 |
| Watts, GF | 1 |
| Billman, GE | 1 |
| Nishijima, Y | 1 |
| Belevych, AE | 1 |
| Terentyev, D | 1 |
| Xu, Y | 1 |
| Haizlip, KM | 1 |
| Monasky, MM | 1 |
| Hiranandani, N | 1 |
| Harris, WS | 1 |
| Gyorke, S | 1 |
| Carnes, CA | 1 |
| Janssen, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)[NCT01492361] | Phase 3 | 8,179 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with a first occurrence of any component of the composite of CV death or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 392 |
| Placebo | 507 |
The primary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, or unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 705 |
| Placebo | 901 |
The key secondary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 459 |
| Placebo | 606 |
Number of patients with an occurrence of CV death during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 174 |
| Placebo | 213 |
Number of patients with a first occurrence of fatal or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 250 |
| Placebo | 355 |
Number of patients with a first occurrence of fatal or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 98 |
| Placebo | 134 |
Number of patients with a first occurrence of non-elective coronary revascularization represented as the composite of emergent or urgent classifications during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 216 |
| Placebo | 321 |
Number of patients with a first occurrence of any component of the composite of total mortality, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 549 |
| Placebo | 690 |
Number of patients with an occurrence of death from any cause during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 274 |
| Placebo | 310 |
Number of patients with a first occurrence of unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 108 |
| Placebo | 157 |
1 review available for eicosapentaenoic acid ethyl ester and Myocardial Infarction
| Article | Year |
|---|---|
Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions.
Topics: American Heart Association; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atheroscler | 2020 |
6 trials available for eicosapentaenoic acid ethyl ester and Myocardial Infarction
| Article | Year |
|---|---|
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
Topics: Aged; Angina, Unstable; Eicosapentaenoic Acid; Endpoint Determination; Female; Humans; Hypertriglyce | 2021 |
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
Topics: Double-Blind Method; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2022 |
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
Topics: Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; | 2022 |
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking.
Topics: Eicosapentaenoic Acid; Humans; Myocardial Infarction; Smoking; Tobacco Products | 2023 |
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
Topics: Aged; Cholesterol, LDL; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglu | 2020 |
Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registr
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Myocardial Infarction; | 2021 |
7 other studies available for eicosapentaenoic acid ethyl ester and Myocardial Infarction
| Article | Year |
|---|---|
Optimizing Dyslipidemic Cardiovascular Residual Risk Reduction With Icosapent Ethyl in Post-MI Patients.
Topics: Dyslipidemias; Eicosapentaenoic Acid; Humans; Myocardial Infarction; Risk Reduction Behavior | 2022 |
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Ei | 2022 |
Effect of icosapent ethyl on susceptibility to ventricular arrhythmias in postinfarcted rat hearts: Role of GPR120-mediated connexin43 phosphorylation.
Topics: Animals; Connexin 43; Eicosapentaenoic Acid; Lipid Regulating Agents; Male; Myocardial Infarction; P | 2020 |
REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES]).
Topics: Aged; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus; Eicosapentaenoic Acid; Eligibili | 2020 |
Icosapent Ethyl (Vascepa) for Hyperlipidemia/Hypercholesterolemia to Reduce Risk of Heart Attack and Stroke.
Topics: Eicosapentaenoic Acid; Humans; Hypercholesterolemia; Lipid Regulating Agents; Myocardial Infarction; | 2021 |
Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: Act now to reduce it.
Topics: Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Eicosapentaenoic Acid; Fema | 2019 |
Effects of dietary omega-3 fatty acids on ventricular function in dogs with healed myocardial infarctions: in vivo and in vitro studies.
Topics: Animals; Calcium; Dietary Supplements; Disease Models, Animal; Docosahexaenoic Acids; Dogs; Dose-Res | 2010 |